Optimizing outcomes in multiple sclerosis - A consensus initiative

P. Coyle, B. Arnason, B. Hurwitz, F. Lublin

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: Initiation of immunomodulators in patients experiencing a clinically isolated syndrome (CIS) may delay progression to clinically definite MS. However, lack of consensus remains on many issues affecting optimal management of MS. Method: A panel of 21 MS experts met during 9 meetings to explore key issues in MS and CIS. Meetings addressed 3 phases: 1. CIS definition and diagnosis; 2. initial therapy; and 3. monitoring disease progression and treatment efficacy. Newsletters covering each phase were sent to 5000 U.S.-based neurologists who were invited to participate in an online survey on key issues. Results: Most panel members agreed that early treatment may minimize neurodegeneration and most would recommend it for patients; that a dose-response relationship exists for beta-interferon therapy; that more aggressive therapy was most effective early in the disease course; and, that MRI has a role in monitoring disease progression. In face of suboptimal response, most would switch patients to a different therapy; while combination therapy would be reserved for those failing monotherapy regimes. Most online survey respondents agreed with these positions. Conclusions: There was uniform consensus from this panel of MS experts that early initiation of immunomodulator therapy was beneficial for CIS patients.

Original languageEnglish
Pages (from-to)S5-S35
JournalMultiple Sclerosis Journal
Issue numberSUPPL. 2
StatePublished - 2009
Externally publishedYes


  • Clinically isolated syndrome
  • Copolymer 1
  • Interferon beta 1a
  • Interferon beta 1b
  • McDonald Criteria
  • Mitoxantrone
  • Multiple sclerosis
  • Natalizumab


Dive into the research topics of 'Optimizing outcomes in multiple sclerosis - A consensus initiative'. Together they form a unique fingerprint.

Cite this